Hormonal
Adjunctive therapies such as pramlintide, metformin, and GLP-1 receptor agonists can improve glycemic control and promote weight loss or weight neutrality in Type 1 Diabetes when added to insulin therapy.
If you have Type 1 Diabetes and are struggling with weight gain from insulin, ask your doctor about adjunctive therapies like pramlintide, metformin, or GLP-1 agonists. These medications may help you lose weight or maintain your weight while improving your blood sugar control. They are not a replacement for insulin but can be added to your regimen.
Pramlintide... is associated with improvements in postprandial and overall glucose control, as well as weight loss... Metformin has been studied most extensively... with benefits on weight, reduction of insulin doses... addition of a glucagon-like peptide-1 (GLP-1) receptor agonist to insulin therapy modestly decreased HbA1c... and body weight.
Why this rating
Supported by meta-analyses and RCTs, but many are small, short-duration, or have limited data in T1D specifically.
Source
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Karen D. Corbin et al. · Endocrine Reviews · 2018
DOI 10.1210/er.2017-00191
More from this paper
- Intensive insulin therapy in Type 1 Diabetes causes significant weight gain, which subsequently increases the risk of cardiovascular disease and metabolic complications.Good
- Insulin manipulation (restriction) to control weight in Type 1 Diabetes leads to chronic hyperglycemia, increased morbidity, and a threefold increase in relative risk of death.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →